Serum neurofilament light chain: a new biomarker for multiple sclerosis

Takeaway

  • Serum neurofilament light chain (sNFL) levels are significantly associated with brain atrophy, disability worsening, and treatment response in people with multiple sclerosis (MS) and may be a potential biomarker.

Why this matters

  • People with MS have multiple therapy options; however, there is no simple blood serum test to assess progression of diseases and treatment response.

  • NFL, which arise from degrading neurons and can be detected in the cerebrospinal fluid and blood serum of people with MS, may be a possible clinical biomarker for people with MS.